Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

bioMérieux S.A.. (3/2/16). "Press Release: 2015 Financial Results".

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 BioFire Diagnostics LLC
  Today BioFire Diagnostics Inc.
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 FilmArray® Torch multiplex PCR system
  Index term 2 Applied Maths–Mérieux: investment, 201601 acquisition €na by bioMérieux
Persons Person Bélingard, Jean-Luc (Mérieux 201101– Président Directeur Général before Ipsen CEO + Pierre Fabre + Roche Diagnostics)
  Person 2 Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)
     


> Strong sales dynamic in 2015, driving 7.1% organic growth for the year
– €1,965 million in sales
– Up 15.7% as reported

> Robust contributive operating income before non-recurring items: €260 million
– In line with target
– Up 14.6% year-on-year

> BioFire ahead of the business plan
– Sustained successful sales performance by FilmArray® and the syndromic approach to the molecular diagnosis of infectious diseases
– FilmArray® Torch cleared by the US FDA in February 2016

> 2016 objectives
– Organic growth in sales of between 6.0% and 8.0%
– Contributive operating income before non-recurring items of between €265 million and €290 million


Jean-Luc Belingard, Chairman, said: "The high-quality performance and ambitious guidance that bioMérieux is announcing today reflect the drive to strengthen our strategic position undertaken in recent years with the support of our long-term family shareholder. We enjoy undeniable competitive advantages, including global market leadership in clinical and industrial microbiology, specialized niche positions in immunoassays, an evenly balanced global geographic footprint, unrivaled expertise in certain areas and a healthy balance sheet. What's more, we now own FilmArray®, a new, forward-facing technology that is gradually becoming the global benchmark in the syndromic molecular testing of infectious diseases. Impelled by Alexandre Mérieux’s leadership we will pursue our operational action plans in order to further improve our performance for the benefit of our customers and their patients."

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux delivered a robust operating performance in 2015. In 2016, the Company expects to maintain a strong sales dynamic while continuing to invest for the long term, particularly in the areas of quality, manufacturing and expanding the innovation pipeline. In a demanding environment and volatile economy, bioMérieux is targeting contributive operating income before non-recurring items of between €265 million and €290 million for the year."
 

Download
[ full press release at http://www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_results_2015.pdf ]

   
Record changed: 2016-03-13

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Mérieux (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px




» top